Format

Send to

Choose Destination
Clin Pharmacol Ther. 2007 Nov;82(5):595-600. Epub 2007 Sep 26.

Advances in the treatment of tuberculosis.

Author information

1
Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA. yzhang@jhsph.edu

Abstract

The current 6-month tuberculosis (TB) therapy is suboptimal with significant side effects and a poor patient compliance problem that frequently selects drug-resistant organisms. The increasing drug-resistant TB problem highlights the need to develop new and more effective drugs. Significant progress has been made recently with several new drug candidates currently in clinical trials. Improved understanding of persister biology and development of persister drugs are likely to be important for developing a more effective therapy.

PMID:
17898708
DOI:
10.1038/sj.clpt.6100362
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center